Showing 4131-4140 of 5314 results for "".
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate
- FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-nemluvio-moderate-severe-atopic-dermatitis/2470663/Galderma’s Nemluvio® (nemolizumab) has received FDA approval for moderate-to-severe atopic dermatitis in patients aged 12 and older, offering a novel treatment option targeting IL-31. According to a press release from Galderma, the approval follows results from the phase III ARCADIA trial
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s
- Melasma Clinical Trials Show Advancements in Inclusive Representationhttps://practicaldermatology.com/news/melasma-clinical-trials-show-advancements-inclusive-representation/2468760/A new analysis of melasma clinical trials indicates progress toward inclusivity, with broad gender, racial, and Fitzpatrick skin type (FST) representation. Researchers publishing in the Journal of Drugs in Dermatology analyzed melasma clinical trials listed on ClinicalTrials.gov,
- Psoriasis Linked with Education, Mood Disorders: Studyhttps://practicaldermatology.com/news/psoriasis-tied-education-and-mood-disorders-study/2468759/A new genetic study has identified six previously unreported loci associated with psoriasis, emphasizing its genetic complexity and links to socioeconomic and mental health factors. The analysis included data from 925,649 individuals across the FinnGen, Estonian Biobank, and UK Biobank, ma
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro